ABSTRACT
Background: Current methods for follow-up of Ovarian Cancer (OC) are widespread, especially with CA125, which, however, is not a perfect biomarker and thus further investigation for new methods of evaluation are warranted. The feasibility of Circulating Tumor Cells (CTCs) in advanced OC was investigated in this case report. Case presentation: A 19-year-old woman with advanced low-grade serous papillary adenocarcinoma and relapsed disease did not have a CA125 correspondent with disease relapse. CTCs were evaluated, compared with CA125 and with image exams. Relapses were not correspondent to elevations of CA125. CTCs demonstrated usefulness, being proportional to major disease relapse, especially in the peritoneum. CTCs may be used as a complementary diagnosis tool when marginal/small increases in CA-125 levels are observed. Conclusions: In OC, CTCs can be an important tool to predict recurrence, response to treatment and improve the quality of decision-making, in order to offer the best treatment to a determined group of patients (AU)
Subject(s)
Humans , Female , Adult , Ovarian Neoplasms/genetics , Adenocarcinoma , Biomarkers, Tumor , Clinical Protocols , Neoplastic Cells, CirculatingABSTRACT
Ameloblastoma is a neoplasm arising from the epithelium involved with the formation of teeth. They are usually benign, locally aggressive and recurrent, however, metastases are rare. The treatment is not clearly defined and the main therapeutic tool is surgical intervention. Radiotherapy and chemotherapy have not been shown encouraging results. As there are few cases reported in the medical literature and the treatment is challenging, we reported a case of a 53-year-old woman with recurrentameloblastoma, with local and distant recurrence, that remains alive over 25 years from diagnosis.